Gilead (GILD) Announces Positive Interim Results on PBC Drug

Gilead Sciences, Inc. (GILD) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar. ASSURE is an open-label study evaluating the long-term safety and efficacy of seladelpar, a once-daily potent and selective peroxisome proliferator-activated receptor (PPAR) delta agonist or delpar. Seladelpar is a first-in-class oral, selective PPAR-delta agonist or delpar is being evaluated for treating primary biliary cholangitis (PBC). The study enrolled adult patients with PBC ...